On May 13, 2025, HC Wainwright & Co. reaffirmed its coverage on Dianthus Therapeutics with a "Buy" rating, maintaining its price target at $40.00 USD. This consistent stance reflects the analyst's ongoing confidence in the potential of Dianthus Therapeutics (DNTH, Financial).
The rating was reiterated by analyst Swayampakula Ramakanth, who continues to see DNTH as a valuable investment opportunity in the biotechnology sector. The unchanged price target suggests that the analyst anticipates steady growth or value preservation for the company in the near future.
Investors should note that the stock's current evaluation aligns with prior assessments, indicating a stable outlook according to HC Wainwright & Co. While the price target remains constant at $40.00 USD, the "Buy" rating reaffirms the analyst's positive sentiment towards DNTH.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Dianthus Therapeutics Inc (DNTH, Financial) is $49.11 with a high estimate of $58.00 and a low estimate of $36.00. The average target implies an upside of 144.58% from the current price of $20.08. More detailed estimate data can be found on the Dianthus Therapeutics Inc (DNTH) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Dianthus Therapeutics Inc's (DNTH, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
